{"nctId":"NCT03945188","briefTitle":"Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis","startDateStruct":{"date":"2019-06-13","type":"ACTUAL"},"conditions":["Ulcerative Colitis"],"count":433,"armGroups":[{"label":"Etrasimod 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Etrasimod"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Etrasimod","otherNames":["APD334"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening\n2. Active UC confirmed by endoscopy\n\nExclusion criteria:\n\n1. Severe extensive colitis\n2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD\n3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Clinical Remission at Week 12","description":"Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Clinical Remission at Week 52","description":"Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Improvement at Week 12","description":"Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Improvement at Week 52","description":"Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.2","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Remission at Week 12","description":"Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Remission at Week 52","description":"Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing at Week 12","description":"Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing at Week 52","description":"Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52","description":"Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52","description":"Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Response at Week 12","description":"Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"34.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Response at Week 52","description":"Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52","description":"Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52","description":"Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \\< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Normalization at Week 12","description":"Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Normalization at Week 52","description":"Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52","description":"Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Remission by Study Visit","description":"Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":null},{"groupId":"OG001","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Complete Symptomatic Remission by Study Visit","description":"Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Non-invasive Clinical Response by Study Visit","description":"Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.7","spread":null},{"groupId":"OG001","value":"42.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"28.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Symptomatic Response by Study Visit","description":"Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":null},{"groupId":"OG001","value":"42.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"28.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline","description":"Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12","description":"Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"17.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":289},"commonTop":["Anaemia","Headache","COVID-19","Colitis ulcerative","Pyrexia"]}}}